Mark Vignola | Intercept Pharmaceuticals, Inc. |
Mark Pruzanski | Intercept Pharmaceuticals, Inc. |
Richard Kim | Intercept Pharmaceuticals, Inc. |
Lisa Bright | Intercept Pharmaceuticals, Inc. |
Sandip S. Kapadia | Intercept Pharmaceuticals, Inc. |
Michael J. Yee | Jefferies LLC |
Jay Olson | Oppenheimer & Co., Inc. |
Salveen Richter | Goldman Sachs & Co. LLC |
Beau Miller | RBC Capital Markets LLC |
Irina Margine | Cowen & Co. LLC |
Steven Seedhouse | Raymond James & Associates, Inc. |
Aspen Mori | Bank of America Merrill Lynch |
Joel L. Beatty | Citi |
Joseph Stringer | Needham & Co. LLC |
Dae Gon Ha | Leerink Partners LLC |
Yanan Zhu | Wells Fargo Securities LLC |
Thank you for joining the Intercept Pharmaceuticals Second Quarter 2018 Financial Results Conference Call. All participants are now in listen-only mode.
Following opening remarks, Intercept's management will open the lines for a question-and-answer period. Please be advised that this call is being recorded at the company's request and the webcast of this call will be archived on the company's website for approximately two weeks. I will now like to introduce Dr.